Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHGI09)

Drug Name

TT20X Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Lymphocyte activation antigen CD30 (TNFRSF8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brentuximab vedotin	DMWLC57	Hodgkin lymphoma	2B30	Approved	[2]
AFM13	DMN45IC	Hodgkin lymphoma	2B30	Phase 2	[3]
Iratumumab	DMI874B	Lymphoma	2A80-2A86	Phase 2	[4]
SGN-30	DMJ9M5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
CAR-T cells targeting CD30	DML0KWM	Non-hodgkin lymphoma	2B33.5	Phase 2	[6]
CAR-T cells targeting CD30	DML0KWM	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
TT11X	DMW3M7X	Hodgkin lymphoma	2B30	Phase 2	[1]
4SCAR19 and 4SCAR30	DMUYFS1	B-cell lymphoma	2A86	Phase 1/2	[8]
Anti-CD30 CAR T cells	DM8139V	Lymphoma	2A80-2A86	Phase 1/2	[9]
CART30	DMLE8T9	Hodgkin lymphoma	2B30	Phase 1/2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation antigen CD30 (TNFRSF8)	TT2GM5R	TNR8_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Tessa Therapeutics
2	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
3	Clinical pipeline report, company report or official report of Affimed Therapeutics.
4	Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
5	The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
6	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
7	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
8	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
9	ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
10	ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas